grant

Multiomic strategies to assess HIV reservoir persistence

Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 Apr 2023Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2025AIDS VirusATACATAC sequencingATAC-seqATACseqAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAfter CareAfter-TreatmentAftercareAnatomic SitesAnatomic structuresAnatomyAnti-HIV PositivityApoptosisApoptosis PathwayAssayAssay for Transposase-Accessible Chromatin using sequencingBasal Transcription FactorBasal transcription factor genesBindingBioassayBiological AssayBloodBlood Reticuloendothelial SystemBlood SampleBlood specimenCAR T cellsCAR modified T cellsCAR-TCAR-TsCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCell BodyCell DeathCell Surface AntigensCell SurvivalCell ViabilityCell surfaceCellsCharacteristicsClinical TrialsCombination immunotherapyDNADataDeoxyribonucleic AcidDetectionDevelopmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFailureGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGenesGeneticGenetic TranscriptionGoalsHIVHIV PositiveHIV PositivityHIV SeroconversionHIV SeropositivityHIV antibody positiveHIV resistanceHIV resistantHTLV-III SeroconversionHTLV-III SeropositivityHeterogeneityHumanHuman Immunodeficiency VirusesIFNImmune mediated therapyImmunological Surface MarkersImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyIn VitroIndividualInfectionInterferonsInterruptionLAV-HTLV-IIILPTNLymphadenopathy-Associated VirusLymphatic TissueLymphoid TissueModalityModelingModern ManMolecular InteractionNon-Polyadenylated RNAOutcomePersonsPredispositionProgrammed Cell DeathPropertyProteinsProvirus IntegrationProvirusesRNARNA ExpressionRNA Gene ProductsResistanceRestRibonucleic AcidSCM-1SCM-1aSCM1SCYC1SamplingSurfaceSurface AntigensSusceptibilitySystemT cells for CART4 CellsT4 LymphocytesTestingTimeTranscriptTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesTransposaseViralViral reservoirVirus reservoirVirus-HIVXCL1XCL1 geneantiretroviral therapyantiretroviral treatmentassay for transposase accessible chromatin followed by sequencingassay for transposase accessible chromatin seqassay for transposase accessible chromatin sequencingassay for transposase-accessible chromatin with sequencingchimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellscombinatorial immunotherapydevelopmentaldual immunotherapyepigeneticallyepigenomeglobal gene expressionglobal transcription profileimmune drugsimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunotherapeuticsimmunotherapy agentin vivoinhibitorinsightintegration sitelatent HIV reservoirlatent HIV-1 reservoirlatent HIV1 reservoirmulti-modalitymultimodalitymultiomicsmultiple omicsnecrocytosisnovelpanomicsperipheral bloodphenotypic biomarkerphenotypic markerpost treatmentresistance mechanismresistantresistant mechanismscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsuccesstranscription factortranscriptometranscriptomics
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Persistence of the latent HIV reservoir in people living with HIV (PLWH) remains the critical barrier to an HIV
cure. Numerous reservoir reduction and control studies have met with only limited success due to our profound

lack of understanding of the cellular mechanisms that allow the HIV reservoir to persist during antiretroviral

therapy (ART).…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →